Real-life clinical management patterns in extensive-stage small cell lung cancer across France: a multi-method study.
Clinical management
Extensive-stage
First-line therapy
Immunotherapy
Small cell lung cancer
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
05 Apr 2024
05 Apr 2024
Historique:
received:
20
07
2023
accepted:
12
03
2024
medline:
6
4
2024
pubmed:
6
4
2024
entrez:
5
4
2024
Statut:
epublish
Résumé
We designed this study based on both a physician practice survey and real-world patient data to: (1) evaluate clinical management practices in extensive-stage small cell lung cancer (ES-SCLC) among medical centers located across France; and (2) describe first-line treatment patterns among patients with ES-SCLC following the introduction of immunotherapy into clinical practice. A 50-item questionnaire was completed by physicians from 45 medical centers specialized in SCLC management. Responses were collected from June 2022 to January 2023. The survey questions addressed diagnostic workup of ES-SCLC, chemoimmunotherapy in first-line and second-line settings, and use of prophylactic cranial irradiation (PCI) and radiotherapy. In parallel, using a chart review approach, we retrospectively analyzed aggregated information from 548 adults with confirmed ES-SCLC receiving first-line treatment in the same centers. In ES-SCLC, treatment planning is based on chest computed tomography (CT) (as declared by 100% of surveyed centers). Mean time between diagnosis and treatment initiation was 2-7 days, as declared by 82% of centers. For detection of brain metastases, the most common imaging test was brain CT (84%). The main exclusion criteria for first-line immunotherapy in the centers were autoimmune disease (87%), corticosteroid therapy (69%), interstitial lung disease (69%), and performance status ≥ 2 (69%). Overall, 53% and 36% of centers considered that patients are chemotherapy-sensitive if they relapse within ≥ 3 months or ≥ 6 months after first-line chemoimmunotherapy, respectively. Among the 548 analyzed patients, 409 (75%) received chemoimmunotherapy as a first-line treatment, 374 (91%) of whom received carboplatin plus etoposide and 35 (9%) cisplatin plus etoposide. Overall, 340/548 patients (62%) received maintenance immunotherapy. Most patients (68%) did not receive radiotherapy or PCI. There is an overall alignment of practices reflecting recent clinical guidelines among medical centers managing ES-SCLC across France, and a high prescription rate of immunotherapy in the first-line setting.
Sections du résumé
BACKGROUND
BACKGROUND
We designed this study based on both a physician practice survey and real-world patient data to: (1) evaluate clinical management practices in extensive-stage small cell lung cancer (ES-SCLC) among medical centers located across France; and (2) describe first-line treatment patterns among patients with ES-SCLC following the introduction of immunotherapy into clinical practice.
METHODS
METHODS
A 50-item questionnaire was completed by physicians from 45 medical centers specialized in SCLC management. Responses were collected from June 2022 to January 2023. The survey questions addressed diagnostic workup of ES-SCLC, chemoimmunotherapy in first-line and second-line settings, and use of prophylactic cranial irradiation (PCI) and radiotherapy. In parallel, using a chart review approach, we retrospectively analyzed aggregated information from 548 adults with confirmed ES-SCLC receiving first-line treatment in the same centers.
RESULTS
RESULTS
In ES-SCLC, treatment planning is based on chest computed tomography (CT) (as declared by 100% of surveyed centers). Mean time between diagnosis and treatment initiation was 2-7 days, as declared by 82% of centers. For detection of brain metastases, the most common imaging test was brain CT (84%). The main exclusion criteria for first-line immunotherapy in the centers were autoimmune disease (87%), corticosteroid therapy (69%), interstitial lung disease (69%), and performance status ≥ 2 (69%). Overall, 53% and 36% of centers considered that patients are chemotherapy-sensitive if they relapse within ≥ 3 months or ≥ 6 months after first-line chemoimmunotherapy, respectively. Among the 548 analyzed patients, 409 (75%) received chemoimmunotherapy as a first-line treatment, 374 (91%) of whom received carboplatin plus etoposide and 35 (9%) cisplatin plus etoposide. Overall, 340/548 patients (62%) received maintenance immunotherapy. Most patients (68%) did not receive radiotherapy or PCI.
CONCLUSIONS
CONCLUSIONS
There is an overall alignment of practices reflecting recent clinical guidelines among medical centers managing ES-SCLC across France, and a high prescription rate of immunotherapy in the first-line setting.
Identifiants
pubmed: 38580937
doi: 10.1186/s12885-024-12117-9
pii: 10.1186/s12885-024-12117-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
421Informations de copyright
© 2024. The Author(s).
Références
Dingemans AC, Früh M, Ardizzoni A, Besse B, Faivre-Finn C, Hendriks LE, et al. Small-cell lung cancer: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up(☆). Ann Oncol. 2021;32(7):839–53.
doi: 10.1016/j.annonc.2021.03.207
pubmed: 33864941
Ganti AKP, Loo BW, Bassetti M, Blakely C, Chiang A, D’Amico TA, et al. Small cell Lung Cancer, Version 2.2022, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(12):1441–64.
doi: 10.6004/jnccn.2021.0058
pubmed: 34902832
pmcid: 10203822
Oronsky B, Abrouk N, Caroen S, Lybeck M, Guo X, Wang X, et al. A 2022 update on extensive stage small-cell Lung Cancer (SCLC). J Cancer. 2022;13(9):2945–53.
doi: 10.7150/jca.75622
pubmed: 35912017
pmcid: 9330463
Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth Edition AJCC Cancer staging Manual: continuing to build a bridge from a population-based to a more personalized approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–9.
doi: 10.3322/caac.21388
pubmed: 28094848
Farago AF, Keane FK. Current standards for clinical management of small cell lung cancer. Transl Lung Cancer Res. 2018;7(1):69–79.
doi: 10.21037/tlcr.2018.01.16
pubmed: 29535913
pmcid: 5835595
Defossez G, Le Guyader-Peyrou S, Uhry Z, Grosclaude P, Colonna M, Dantony E et al. Estimations nationales de l’incidence et de la mortalité par cancer en France métropolitaine entre 1990 et 2018. Volume 1– Tumeurs solides. Saint–Maurice (Fra): Santé publique France. 2019. 372 p.
Delafosse P, Defossez G, Molinié F, D’Almeida T, Lecoffre C, Lafay L, et al. Survie Des personnes atteintes de cancer en France métropolitaine 1989–2018 - Poumon cancer à petites cellules. Boulogne-Billancourt: Institut National du Cancer; 2021. p. 10.
Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell Lung Cancer. N Engl J Med. 2018;379(23):2220–9.
doi: 10.1056/NEJMoa1809064
pubmed: 30280641
Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929–39.
doi: 10.1016/S0140-6736(19)32222-6
pubmed: 31590988
Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N, et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung Cancer treated with atezolizumab, carboplatin, and Etoposide (IMpower133). J Clin Oncol. 2021;39(6):619–30.
doi: 10.1200/JCO.20.01055
pubmed: 33439693
pmcid: 8078320
Paz-Ares L, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022;7(2):100408.
doi: 10.1016/j.esmoop.2022.100408
pubmed: 35279527
pmcid: 9161394
Falchero L, Tissot C, Paulus V, Duruisseaux M, Souquet PJ, Planchard D. Référentiels Auvergne Rhône-Alpes en Oncologie Thoracique 2023: Cancer Bronchiques à Petites Cellules. 2023. http://referentiels-aristot.com/wp-content/uploads/02_CPC_2023_txt-integral.pdf . Accessed 19 July 2023.
Keogh A, Finn S, Radonic T. Emerging biomarkers and the changing Landscape of Small Cell Lung Cancer. Cancers (Basel). 2022;14(15):3772.
doi: 10.3390/cancers14153772
pubmed: 35954436
Liu X, Xing H, Liu B. Current status and future perspectives of immune checkpoint inhibitors in extensive-stage small cell lung cancer. Am J Cancer Res. 2022;12(6):2447–64.
pubmed: 35812062
pmcid: 9251690
von Itzstein MS, Gonugunta AS, Mayo HG, Minna JD, Gerber DE. Immunotherapy Use in patients with Lung Cancer and Comorbidities. Cancer J. 2020;26(6):525–36.
doi: 10.1097/PPO.0000000000000484
Falchero L, Guisier F, Darrason M, Boyer A, Dayen C, Cousin S, et al. Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: results of the IFCT-1905 CLINATEZO real-world study. Lung Cancer. 2023;185:107379.
doi: 10.1016/j.lungcan.2023.107379
pubmed: 37757576
Sagie S, Maixner N, Stemmer A, Lobachov A, Bar J, Urban D. Real-world evidence for immunotherapy in the first line setting in small cell lung cancer. Lung Cancer. 2022;172:136–41.
doi: 10.1016/j.lungcan.2022.08.015
pubmed: 36087486
Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME. Use of Immune checkpoint inhibitors in the treatment of patients with Cancer and Preexisting Autoimmune Disease: a systematic review. Ann Intern Med. 2018;168(2):121–30.
doi: 10.7326/M17-2073
pubmed: 29297009
Cortellini A, Buti S, Santini D, Perrone F, Giusti R, Tiseo M, et al. Clinical outcomes of patients with Advanced Cancer and Pre-existing Autoimmune diseases treated with anti-programmed Death-1 immunotherapy: a real-world transverse study. Oncologist. 2019;24(6):e327–37.
doi: 10.1634/theoncologist.2018-0618
pubmed: 30796151
pmcid: 6656514
Azar I, Yazdanpanah O, Jang H, Austin A, Kim S, Chi J, et al. Comparison of Carboplatin with Cisplatin in Small Cell Lung Cancer in US veterans. JAMA Netw Open. 2022;5(10):e2237699.
doi: 10.1001/jamanetworkopen.2022.37699
pubmed: 36264573
pmcid: 9585434
Rossi A, Di Maio M, Chiodini P, Rudd RM, Okamoto H, Skarlos DV, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012;30(14):1692–8.
doi: 10.1200/JCO.2011.40.4905
pubmed: 22473169
Schoenmaekers J, Hofman P, Bootsma G, Westenend M, de Booij M, Schreurs W, et al. Screening for brain metastases in patients with stage III non-small-cell lung cancer, magnetic resonance imaging or computed tomography? A prospective study. Eur J Cancer. 2019;115:88–96.
doi: 10.1016/j.ejca.2019.04.017
pubmed: 31129385
Guirado M, Fernández Martín E, Fernández Villar A, Navarro Martín A, Sánchez-Hernández A. Clinical impact of delays in the management of lung cancer patients in the last decade: systematic review. Clin Transl Oncol. 2022;24(8):1549–68.
doi: 10.1007/s12094-022-02796-w
pubmed: 35257298
pmcid: 8900646
Kim SH, Jo EJ, Mok J, Lee K, Kim KU, Park HK, et al. Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line treatment for extensive-stage small cell lung cancer. Korean J Intern Med. 2023;38(2):218–25.
doi: 10.3904/kjim.2022.361
pubmed: 36800677
pmcid: 9993105
Khalifa J, Lerouge D, Le Péchoux C, Pourel N, Darréon J, Mornex F, et al. Radiotherapy for primary lung cancer. Cancer Radiother. 2022;26(1–2):231–43.
doi: 10.1016/j.canrad.2021.11.005
pubmed: 34953709